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Introduction
Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder characterized by unexplained left ventricular hypertrophy (LVH) in the absence of other predisposing clinical conditions.
1 Mutations in the protein components of the sarcomere cause HCM. Hypertrophic remodeling also occurs in disorders that clinically mimic HCM, including Fabry disease (GLA mutations), glycogen cardiomyopathy (PRKAG2 mutations) and Danon disease (LAMP2 mutations). 2 More than 1,400 different mutations in at least 8 sarcomere protein genes have been reported in HCM. 3, 4 Even though a majority (~80%) of HCM mutations alter the cardiacmyosin heavy chain (MYH7) or cardiac myosin binding protein-C (MYBPC3) genes, 5 most are "private" and unique to a specific family. The diverse molecular etiology of HCM, combined with background genomic variability and lifestyle differences among HCM patients, has hindered definitive insights into genotype and phenotype relationships.
3-6
Previous studies estimate that HCM occurs in approximately 1 in 500 individuals in the United States, 7 but the population prevalence of pathogenic mutations in genes that encode sarcomere proteins or other hypertrophic molecules is unknown. Capitalizing on the geographic isolation and homogeneous population in Iceland, we undertook population-based clinical and genetic studies of HCM. Iceland, an island with a population of 320,000, has no tertiary HCM referral center, and genetic testing of HCM patients has not been widely used in clinical practice.
Genetic analyses of only two Icelandic HCM families have been reported; in both, a MYBPC3 mutation was identified that causes an adenine-to-guanine transition in intron 12 (c.927-2A>G). 8 This mutation is predicted to alter RNA splicing and result in a frame shift that leads to premature termination and a truncated protein. We performed cascade genetic analyses, initially myosin heavy chain (MYH7) or cardiac myosin binding protein-C (MYBPC3) ge en n nes, s s 5 5 5 m m mos os ost t t ar ar a e e "private" and unique to a specific family. The diverse molecular etiology of HCM, combined y wi with th h b b ba ac ackg kg kgro ro r u u und d d g ge genomic variability and lifesty y yle le le d d differences amo mo ong g H H HC C CM patients, has h hi hind d der e ed defin nit itiv iv i e e e in insi s s gh gh ghts ts ts i i int nt nto o ge ge gen no not ty yp p pe and nd nd phe e en noty y yp pe pe r re el e a at atio ions nshi hips ps. .
3--6 6 sequencing patient samples for MYBPC3 c.927-2A>G and then sequencing other genes known to cause HCM and hypertrophic remodeling. Our data identify the prevalence of clinical hypertrophy and HCM in Iceland, define the contribution of gene mutations, and reveal the phenotypic spectrum and associated risk for adverse outcomes of a prevalent MYBPC3 mutation.
Materials and methods

Ethical considerations
This study was performed with the approval of the National Bioethics Committee of Iceland, the Icelandic Data Protection Authority, and the Partners Human Research Committee, with informed consent obtained from subjects.
Subjects
Patients with a clinical diagnosis of HCM were identified from surveys of electronic medical nformed consent obtained from subjects.
Pa ati ti ien en ents ts ts w w wit it ith h h a cl cl lin in inic i al diagnosis of HCM were i i ide de d n ntified from sur ur u veys ys s o o of electronic medical
e eco o ord r s and re evi vi iew ew ew o of f f Ic c cel el elan an andi di dic c ec ec cho ho hoc ca ar rd diog g gra a am d d da at tab bas as ses es, , , in n ncl clu ud udin ing g th t the e e Na Na ati ti ion onal al al U U Uni ni ive ve er rs rsit t ity y provided additional clinical data, family medical histories and blood samples for genetic testing.
All death certificates, hospital records and autopsy reports of enrolled subjects were reviewed again in October-November 2012.
The following clinical variables were registered: age at diagnosis; family history of HCM; hypertension; atrial fibrillation (intermittent/persistent); New York Heart Association (NYHA) functional class at diagnosis and at last contact; coronary artery disease (defined as 50% narrowing in 1 epicardial vessel); medications at study visit; and HCM events, including cardioverter-defibrillator (ICD) implantation, appropriate ICD therapy for ventricular tachycardia/fibrillation (VT/VF, defined as shock or anti-tachycardia pacing), septal reduction therapy (surgical septal myectomy or alcohol septal ablation), heart failure (documented symptomatic and hemodynamic deterioration), 9 cardiac transplantation, stroke and sudden death (SD, recorded as unexpected non-traumatic pre-mature death within 1 hour after the onset of symptoms, including un-witnessed, unexpected nocturnal death). Risk factors for SD 1 were recorded, including (1) a family history of 1 HCM-related SD; (2) non-sustained ventricular tachycardia (NSVT, defined as one or more runs of 6 consecutive ventricular extra-systoles at a rate of more than 120 beats per minute); (3) unexplained syncope; (4) abnormal blood pressure response (defined as a failure of the systolic blood pressure to rise by more than 20 mmHg from baseline values, or a fall of more than 10 mmHg from the maximum blood pressure during upright exercise) and (5) massive LV hypertrophy (thickness 30 mm). HCM adverse cardiac events were defined as SD, ICD appropriate therapy, heart failure death, stroke death or cardiac 50% narrowing in 1 epicardial vessel); medications at study visit; and HCM ev ev ven n nts ts, , in in incl cl clud ud udin ing g cardioverter-defibrillator (ICD) implantation, appropriate ICD therapy for ventricular a ach ch hyc yc yca ar ardi di dia/ a/ a/fi fi fibr ril il lla la lati tion (VT/VF, defined as shock ck ck o or r anti-tachyca ard rd r ia p p pac ac acin i g), septal reduction h h her r rap a y (surgi ica cal l l s sept ptal a a m m mye yect ct cto om omy y y o or or a alc c coho o ol sept ta tal l ab b bla la ati tio on n) ), ), h he ea eart rt f fai ai ailu ure re ( ( (do do docu cume me ment nted ed e y ymp mp mpto to toma mati ti tic c c an and d d h he hemo m mody dy dyna nami mi m c c c de de dete te teri rior or orat at atio io ion) ) ), , 9 9 c c car ard dia a ac t t tra ra rans nspl pl plan an nta ta ati ti tion on n, st st s ro ro oke ke ke a and nd nd s sud d dde e en n d d dea at ath h SD, recorde ed d d as as a u u une ne nexp xp x ec e e te te ed d d no no on-n-n tr tr rau au a ma ma m ti ti tic c c pr pr pre-e-e ma ma matu tu ure re d d dea ea eath th h w w wit it ithi hin n n 1 1 1 h h hou ou our r r af af fte te ter r r th th the e e on o set of transplantation.
Echocardiography and cardiovascular magnetic resonance
Transthoracic echocardiographic studies were performed with commercially available instruments according to the standards at each echocardiography lab. Echocardiograms were limited to a few centers with expertise and were not over-read. Maximum LV wall thickness represented the largest dimension measured at any site within the LV chamber at end-diastole.
Left atrial and left ventricular end-diastolic cavity dimensions (LVEDD) were assessed by Mmode echocardiography. The peak instantaneous LV outflow gradient was estimated with continuous wave Doppler ultrasound under basal conditions. End-stage HCM was defined as an ejection fraction <50% and dilated LV (LVEDD >58 mm). Cardiac magnetic resonance studies were performed with a clinical scanner (Siemens Magnetom Avanto B17) in 34 patients. Late gadolinium enhancement images were acquired.
Genetic analyses
Genetic analyses were performed on 141 HCM patients (137 surviving and 4 previously consented deceased patients). Genomic DNA was extracted from whole blood samples and studied using a cascade strategy. HCM patients were initially screened for the MYBPC3 c.927-2A>G mutation that was previously reported in two Icelandic families. 8 Mutation-negative samples (n=61) were studied using targeted capture sequencing of 8 sarcomeric protein genes (ACTC, MYBPC3, MYH7, MYL2, MYL3, TNNI3, TNNT2, and TPM1) and the lysosomal associated membrane protein-2 (LAMP2) and alpha-galactosidase A (GLA) genes. Due to technical issues, the protein kinase AMP-activated, noncatalytic, -2 (PRKAG2) gene was sequenced only in a subset (n=34) of mutation-negative samples.
The MYBPC3 c.927-2A>G mutation was ascertained by sequencing PCR-amplified ejection fraction <50% and dilated LV (LVEDD >58 mm). Cardiac magnetic res son on onan a a ce ce c s s stu tu tudi d dies e
were performed with a clinical scanner (Siemens Magnetom Avanto B17) in 34 patients. Late ga gado do doli li lini ni nium um m en nhan an anc ce cement images were acquired.
G G Gen ne netic analys yse e es
Ge Ge ene ne n ti ti tic c c an an nal al aly ys yses es s w w wer ere e e pe pe perf rfor r c.927-2A>G mutation (n=61) were studied further. Genomic libraries were prepared from 1-2 g of genomic DNA (as previously described) 10, 11 using custom adapters that included a unique 3-base-pair barcode followed by a thymine residue. Sequencing was performed on an Illumina HiSeq2000, producing 50-base-pair pairedend reads (Illumina, CA). All filtered reads were mapped to the human reference genome (hg19) using Novoalign (Novocraft.com). Picard HsMetrics was subsequently used to evaluate sequencing quality (picard.sourceforge.net). All single-nucleotide variants and small indels were called using GATK Unified Genotyper. 12 On average, libraries were sequenced to 4 million En En nri ri r ch ch chme me m nt nt nt; ; ; A Ag Agi il ile en nt, t, C CA A) A) tha ha hat we we were re re d de e esig ig igne ne ned to to to co c cov v ver r r al al ll l l e ex exon on ons s of of f 6 6 6 s sa a arc c com om mer er ere e e pr pr prot ot otein n n g ge gene ne es Thirty-seven individuals with the MYBPC3 c.927-2A>G mutation were genotyped using Illumina SNP chips and had their genotypes long-range phased. 14 The age of the MYBPC3 c.927- where t is the age of the mutation in generations, is the recombination rate between the mutation and the SNP, x is the frequency of chromosomes carrying both the mutation and the SNP allele that has a higher frequency of the mutation on its background, and y is the frequency of chromosomes carrying the mutation and the other SNP allele. 16 These age estimates were then corrected based on the Luria-Delbrück model, which takes into account the impact of population growth as follows:
, where r is the rate of past exponential population growth, which we estimate as 0.3. 18 A single estimate for the age of the mutation in generations was then obtained by taking the geometric mean of the age estimates for each SNP, which was then multiplied by 30 to obtain an estimate of the age of the mutation in years.
Statistical analysis
Descriptive data are expressed as discrete numbers or percentages. Data are displayed as the mean ± standard deviation for continuous variables and as proportions for categorical variables.
Student´s t-tests were used for continuous variables, with -square tests or Fisher´s exact tests used for categorical variables. P-values <0.05 were considered significant. Kaplan-Meier curves were compared using nonparametric log-rank testing. Expected survival appropriate to age and sex was based on data from Statistics Iceland. 19 The actual and expected hazard rates were compared using nonparametric log-rank testing.
Results
Demographics of HCM in Iceland
growth, which we estimate as 0.3. 18 A single estimate for the age of the mutation in generatio i ns was s th th hen en en o o obt bt tai a a ne e ed d d by b taking the geometric mean n o o of f f the age estimates fo fo for r r each SNP, which was h h hen n n multipl lie ied d by by by 3 30 0 0 t to to o obt bt btai ai in n n an an an e e est st tim im imat ate e e of of of t the h a ag ge o o of f f th th the e mu mu mut ta tati ti tion on on i i in n y year ar rs. s. s.
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The review of medical records between 1997 and 2010 in patients with cardiac hypertrophy identified 180 patients with clinical criteria for HCM (Figure 1 ). All except one of these patients were of Icelandic origin. As HCM exhibits age-related penetrance, we calculated the prevalence of clinical HCM among 237,500 adults in Iceland 19 at 1 in 1,600 individuals.
Longitudinal clinical information on HCM patients, summarized in Table 1 Cardiac magnetic resonance imaging studies in 34 patients showed late gadolinium enhancement in 25 (74%). Fifty-one patients (28%) had atrial fibrillation, including 20 (11%) with persistent atrial fibrillation. Coronary arteriograms or computed tomography angiograms performed for clinical indications in 73 (41%) patients revealed clinically significant atherosclerotic coronary artery disease in 13 patients (7.2%). Hypertension was present in 18 patients (10%).
Female HCM patients (34% of the cohort) were diagnosed at a mean of 7 years later than men (p=0.011) but experienced more heart failure symptoms than men. Sixty percent of female patients were classified as NYHA functional class II or higher, compared to 35% of men (p=0.016). Female patients were more often treated with diuretics (p=0.0020), and only 13% of female patients required no medical treatment compared to 28% of male patients (p=0.022).
Thirty-five (19%) of the initial 180 HCM patients were deceased (mean age at death = C C Car rd rdiac magn net etic ic i r r res so o onan an anc ce ce i i im ma magi gi gin ng ng s s stu u udies s s i in 34 4 4 p p pati ie ien nt nts s sh h how ow wed d l lat ate e e g ga gado do doli li lini nium um um e enh nh nhan an ance ce em m ment n n 2 2 25 5 (7 (7 (74% 4% %). ). ). F Fif ift ty ty--o -one ne e p p pat atie i n nt nts (2 (2 (28% 8% 8%) ) ha ha had d d a at atri i ial al al f f fib ibr rill l lat at tio io ion n, n, i inc nc n lu lu udi di ding ng n 2 20 0 0 (1 (11% 1% 1%) ) ) wi wi wit th th p p per r rsi sist st ten en nt t atrial fibrillat atio io ion. n. n C C Cor or o on on onar a y y y ar ar arte eri ri riog og ogra ra r ms ms ms o o or r co co comp mp mput ut uted ed ed t tom om omog og ogr rap ap aphy hy h a a ang ng ngio io 
Genetic analysis
DNA analyses were performed in 141 HCM patients, including 137 survivors and 4 consented, deceased patients (Figure 1) . The MYBPC3 c.927-2A>G mutation was identified in 76 surviving (55%) and the four deceased patients. Using the Icelandic genetic genealogical database, we also imputed the MYBPC3 c.927-2A>G mutation in 8 of 10 HCM patients. In total, 88 Icelandic HCM patients carried the MYBPC3 c.927-2A>G mutation ( Table 2) .
Additional genetic analyses in 61 patients without the MYBPC3 c.927-2A>G mutation revealed variants in sarcomere protein genes and in the GLA gene ( Table 2) . No pathogenic or likely pathogenic variants were identified in LAMP2 or PRKAG2.
Nine patients presented eight MYBPC3 or MYH7 variants; of these, four were likely CDs or external defibrillation, at a mean age of 44.6 years ± 19.5. The incidenc ce e e of of f V V VT/ T/ T/VF VF VF w was 0.48%/year, and the annual SD mortality rate was 0.17%/year. Non-HCM related deaths oc ccu cu curr rr red ed ed i i in n n 17 17 1 p pat at ati ie ients, including 12 due to non-n-ca ca c r rdiac causes a and nd n 5 d d due ue ue to coronary artery d di dise e eas a e or mul ulti ti i--or r rgan an n c ca au ause se ses. s. s.
Ge Ge ene ne neti ti tic c c an an nal al alys ysi is s
DNA analys ses es s w w wer er ere e e pe pe perf rf r or r rme me med in in in 1 141 4 4 H H HCM CM CM p p pat at a ie ie ent nt n s, s, s, inc nc nclu lu udi di ding ng ng 1 1 137 7 7 s s sur ur urvi vi vivo vo vors rs a a and nd nd 4 4 4 c c consented, pathogenic, two were variants of unknown significance (VUS), and 2 were likely benign. [20] [21] [22] [23] [24] Two patients shared the likely pathogenic variant MYBPC3 c. 
Familial clustering
We assessed the Decode genealogical database to assess the familial relationships of study Based on Decode genomic genealogic data on 98,721 Icelanders, the shared chromosome 11 haplotype that contains the MYBPC3 c.927-2A>G mutation has a predicted population prevalence of 0.36%. To assess the penetrance of the MYBPC3 mutation, we defined the Icelandic population over the age of 42 years (the mean age at diagnosis for patients studied here) during the study period from 1997 to 2010. 19 Among these 116,600 adult Icelanders, we predict that 420 individuals carry the MYBPC3 c.927-2A>G mutation, whereas only 88 mutation carriers (80 by sequence analyses and 8 by imputation), corresponding to 21% of the expected number, were clinically identified. Unrecognized HCM in mutation carriers, premature death from HCM, and incomplete penetrance may account for differences between the predicted and observed prevalence of HCM caused by MYBPC3 c.927-2A>G.
Genotype-phenotype correlations
We compared clinical manifestations and adverse outcomes (Table 3) c.927-2A>G carriers and mutation-negative patients. However, risk factors for adverse cardiac events were increased among patients with the MYBPC3 c.927-2A>G mutation, although not all reached statistical significance. Compared with mutation-negative patients, mutation-positive patients had more NSVT (n=20, 23%), massive hypertrophy (n=16; 18%) and abnormal blood pressure responses (n=9; 10%). Consistent with an increased risk, adverse cardiac events occurred more frequently in HCM patients with the MYBPC3 c.927-2A>G mutation than in mutation-negative patients (p=0.010; Figure 4b) . Importantly, the risk for adverse events extended to family members; compared to mutation-negative patients, carriers of the MYBPC3 c.927-2A>G mutation demonstrated more frequent HCM SD in family members (n=38, 43%).
Among 12 (14%) MYBPC3 c.927-2A>G mutation carriers with an ICD implanted, seven (58%)
48.5 ± 17.7 years; p 0.50 for each comparison).
We observed no significant differences in maximum LV wall thickness, LV outflow ob bst st stru ru ruct ct ctio io ion, n, n, l le eft t at at atr ri rial dimensions, LVEDD, NY Y YHA HA HA functional cl las as a s, o or r r t th the prevalence of co on nc ncomitant hy hyp p per r rten ensi s on on on, at at atri ri rial al f f fib ib ibri ri r l ll la at t tion, , s strok ke ke and The founder mutation in the Icelandic population, similar to previously described founding mutations in Finland, 28 the Netherlands, 29 India, 30, 31 Japan, 32 South-Africa, 33 Spain, 34 France, 35 19 Approximately 50% of the mortality in HCM patients was HCM-related (0.78%/year) and occurred at a mean age of 68 compared to 81 years for non-HCM related mortality (p=0.022). Patients with non-HCM related mortality were older at diagnosis compared to patients with HCM-related mortality, a finding in concordance with prior data.
39
HCM mortality was commonly due to heart failure, often at an advanced age. 19 The id den enti t t f f fica cati t t on on n o o of f a a pr pred ed do om omin ina ant fo fou und der r r mu u ut ta tati tion on on i in n Ic Icel elan and d p pr prov ov ovi id ided ed d a r r rar are e op oppo po port rt rtun un u it ity y y to to to a as s sse es ess s l lon ng ngit i ud ud udi ina na nal l l cl cl clin inic ic i al al al r r re e elat at atio io i n n nsh h hips ps ps b b be e etw tw twee ee een n ge ge eno no n ty ty type pe e a and nd nd p p phe he hen n noty ty ype e e. H HC HCM M M n Iceland is a a a ch ch chro ro roni ni n c c c an an a d d ma ma mana na age ge g ab ab able e e d d dis is isea ea ease se se w w wit it th h h mi mi m ni ni nima ma mal l l im im impa pa p ct ct ct o o on n n li li life fe fe e exp xp xpec ec ecta ta anc nc n y. Similar HCM patients (84.8 ± 4.4 years of age) died from diastolic heart failure after reaching normal life expectancy, underscoring that normal longevity can be achieved in HCM.
In contrast to these overall favorable characteristics among all Icelandic HCM patients, the clinical course associated with the MYPC3 c.927-2A>G mutation was poorer. In comparison to mutation-negative HCM, patients with the MYPC3 c.927-2A>G mutation were diagnosed at a younger age due to clinical presentation rather than via family screening. Patients with the MYPC3 c.927-2A>G mutation also had higher rates of adverse cardiac events including serious arrhythmias, appropriate ICD therapies, and SD. These data have important medical implications for the estimated 1,150 carriers of the MYBPC3 c.927-2A>G mutation in Iceland who are at risk for HCM and these adverse events. Thus, cascade gene-based testing in Iceland is ongoing.
Our study design had several sources of potential bias. First, this was fundamentally a study of survivors; we did not include affected individuals who died, possibly from HCM prior to its clinical presentation, which may have led to an underestimation of the morbidity and mortality. Second, clinical data were collected retrospectively. Finally, genetic analyses of the patients with the MYBPC3 c.927-2A>G mutation were limited to the identification of this mutation, and we therefore cannot exclude the possibility that compound mutations contributed to clinical phenotypes in these patients. Although compound HCM mutations typically produce a more severe disease, these are uncommon and typically are identified in less than 5% of HCM patients.
40, 41
Despite these limitations, our study provides the first estimate of the population prevalence of HCM diagnosed by clinical criteria and genetic testing. These findings demonstrate that the MYBPC3 c.927-2A>G mutation increases the risk for adverse outcomes in HCM.
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Supplemental Methods
Genetic Analyses
Capture probe design
Capture probes (biotinylated RNA library baits) were designed using eArray, a publicly available web-based probe design application (https://earray.chem.agilent.com) (Agilent Technologies, CA). All custom probes were synthesized and PCR-amplified using universal primers connected to the probes, then amplified and biotin-conjugated by in vitro transcription (Agilent Technologies, CA).
Solution-based hybridization
We performed solution-based hybridization and target enrichment according to the manufacturer's protocol with some modifications (Agilent Technologies, CA). Each pool of DNA for target enrichment was prepared by adding human Cot-1 DNA, salmon sperm DNA, and blocking oligonucleotides. Separately, a unit of oligo capture library (ELID# 0382021) was combined with RNAse block and hybridization buffer. Subsequently, each pool was added to the oligo capture library and incubated for 24 hours at 65°C.
After the hybridization, the captured subgenomic DNA was selected using streptavidincoated magnetic beads (Invitrogen, CA) and eluted with the MinElute PCR purification kit (Qiagen, CA). The subgenomic targets were enriched by PCR amplification and sequenced.
Variant Classification
Variants were mainly categorized into likely pathogenic, variant of unknown significance 
